文献速递骨软组织肉瘤与黑色素瘤

免疫检查点抑制剂治疗软组织肉瘤的系统综述与荟萃分析

Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2021-06-06

该系统综述与荟萃分析纳入27项前瞻性临床试验共1012例软组织肉瘤患者,评估免疫检查点抑制剂的活性。汇总客观缓解率为0.14(95%CI 0.09-0.18),疾病控制率为0.55(95%CI 0.43-0.66)。免疫检查点抑制剂的活性因组织学亚型、疾病设置和联合治疗策略而异。

要点

  • 汇总ORR为0.14,未达到预设的临床活性阈值0.15
  • 经典卡波西肉瘤、腺泡状软组织肉瘤和未分化多形性肉瘤缓解率较高
  • 胃肠道间质瘤、子宫平滑肌肉瘤等亚型活性有限

核心结论

  • 免疫检查点抑制剂在软组织肉瘤中的临床活性高度可变,取决于组织学亚型、疾病设置和联合治疗策略。

研究设计与样本

  • 系统综述检索MEDLINE、Embase和Cochrane中心对照试验注册库,并检索2017至2020年ESMO、ASCO和CTOS会议摘要。
  • 纳入27项前瞻性临床试验,共1012例软组织肉瘤患者,涵盖超过25种组织学亚型。

主要发现

  • 汇总客观缓解率为0.14(95%CI 0.09-0.18),疾病控制率为0.55(95%CI 0.43-0.66)。
  • 中位无进展生存期范围为1.8-11.5个月,中位总生存期范围为6.1-34.7个月。
  • 按治疗类别汇总ORR:抗PD1单药0.14(95%CI 0.07-0.23),抗PD1+抗CTLA4为0.16(95%CI 0.06-0.29),抗PD1+TKI为0.20(95%CI 0.06-0.38),抗PD1+化疗为0.20(95%CI 0.06-0.38),抗PD1+免疫调节剂为0.08(95%CI 0.01-0.19)。
  • 按疾病设置汇总ORR:新辅助治疗0.09(95%CI 0.00-0.25),晚期一线治疗0.23(95%CI 0.15-0.32),晚期经治0.13(95%CI 0.09-0.19)。
  • 高缓解率亚型:经典卡波西肉瘤ORR 0.69(95%CI 0.51-0.82),腺泡状软组织肉瘤ORR 0.35(95%CI 0.27-0.44),未分化多形性肉瘤ORR 0.20(95%CI 0.15-0.27)。

关键数值与推荐

  • 临床活性cut-off定义为客观缓解率≥0.15。
  • 活性有限亚型:胃肠道间质瘤ORR 0.01(95%CI 0.0-0.08),子宫平滑肌肉瘤ORR 0.06(95%CI 0.02-0.18),平滑肌肉瘤ORR 0.10(95%CI 0.06-0.17),脂肪肉瘤ORR 0.11(95%CI 0.07-0.17)。

临床怎么用

  • 在经典卡波西肉瘤、腺泡状软组织肉瘤和未分化多形性肉瘤中可考虑免疫检查点抑制剂治疗。
  • 早期将免疫检查点抑制剂与化疗联合似乎是值得进一步关注的有前景策略。

局限性

  • 纳入研究间异质性可能影响汇总结果,各亚型样本量有限。
  • 需要转化研究整合分子特征、生物学行为和对免疫检查点抑制剂的反应来确定其治疗地位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Soft-tissue sarcomas (STSs) are rare malignancies, accounting for approximately 1% of adult cancer. Metastatic disease carries a poor prognosis, and various efforts have been made to improve the prognosis of advanced STS, to date with little success. Immune checkpoint inhibitors (ICPIs) have substantially improved prognosis for many cancer types. Their role in the treatment of STS, however, remains unravelled. OBJECTIVE: The objective of the study is to assess the activity of ICPIs in the treatment of STS. METHODS: We performed a systematic review using MEDLINE, Embase and Cochrane Central Register of Controlled Trials. Furthermore, abstracts from European Society of Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO) and Connective Tissue Society Oncology (CTOS) congress were searched from 2017 until 2020. Prospective clinical trials investigating ICPIs, either monotherapy or combination therapy, in STS were available for inclusion. The outcomes of interest were objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and major toxicity. Cut-off for clinical activity was defined as an ORR of ≥0.15. Subgroup analysis was carried out as per treatment category, disease setting and histologic subtype, using a random effects model. RESULTS: We identified 27 studies, including a total of 1012 patients (range 6-85) with more than 25 histologic subtypes. The pooled ORR was 0.14 (95% confidence interval [CI] 0.09-0.18), DCR was 0.55 (95% CI 0.43-0.66), mean PFS range was 1.8-11.5 months and mean OS was 6.1-34.7 months. The pooled ORR as per treatment category was 0.14 for anti-programmed cell death 1 (anti-PD1) monotherapy (95% CI 0.07-0.23), 0.16 for anti-PD1 + anti-cytotoxic T-lymphocyte-associated protein 4 (95% CI 0.06-0.29), 0.20 for anti-PD1 + tyrosine kinase inhibitor (95% CI 0.06-0.38), 0.20 for anti-PD1 + chemo (95% CI 0.06-0.38) and 0.08 for anti-PD1 + immunomodulator (95% CI 0.01-0.19). The pooled ORR as per disease setting was as follows: neoadjuvant treatment, 0.09 (0.00-0.25); advanced disease first line, 0.23 (0.15-0.32) and advanced pretreated, 0.13 (0.09-0.19). High response rates were seen in classic Kaposi sarcoma (CKS), alveolar soft part sarcoma (ASPS) and undifferentiated pleomorphic sarcoma (UPS) with ORR of 0.69 (95% CI 0.51-0.82), 0.35 (95% CI 0.27-0.44) and 0.20 (95% CI 0.15-0.27), respectively. Activity was limited in gastrointestinal stromal tumour (ORR 0.01 [95% CI 0.0-0.08]), uterine leiomyosarcoma (ORR 0.06 [95% CI 0.02-0.18]), leiomyosarcoma (ORR 0.10 [95% CI 0.06-0.17]) and liposarcoma (ORR 0.11 [95% CI 0.07-0.17]). CONCLUSION: Clinical activity of ICPIs in STS is highly variable and depends on histologic subtype, disease setting and concomitant treatment strategy. Activity was high in CKS, ASPS and UPS. Early incorporation of ICPIs in combination with chemotherapy seems a promising strategy that warrants further interest. Translational research integrating molecular profile, biological behaviour and response to ICPIs should determine their role in treatment of STS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Saerens M, Brusselaers N, Rottey S, et al. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. Eur J Cancer. 2021. PMID: 34107450. doi:10.1016/j.ejca.2021.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。